Once again, teamwork makes the (HFrEF) dream work. Engage your pharmacists, they help overcome clinical inertia and improve GDMT.
https://t.co/D0Is46xDDm
📢 Generic Entresto is now available at Cost Plus Drugs ❗️
Sacubitril/Valsartan is now on https://t.co/HixgZoTxWB. A big step forward for those managing chronic heart failure.
Available in:
💊 24mg/26mg 30 tablets - $33.75 - https://t.co/TN4CzXDlyN
💊 49mg/51mg 30 tablets - $33.75 - https://t.co/PFy11OjWY2
💊 97mg/103mg 30 tablets - $33.75 - https://t.co/DXgs7wWMA1
➡️ No membership fees. No insurance needed. Just transparent pricing! Sign up today at https://t.co/Xk3eIxk7KS
⭐️ Thank you to Ascend Laboratories for making this possible!
🚨New in @JACCJournals w #ACC24
🇺🇸 analysis of newly diagnosed #HFrEF
>4 in 5 pts eligible for quad GDMT
Yet, <1 in 6 prescribed it.
Potentially completely generic triple GDMT (RASi + BB + MRA)??.....only ~4 in 10 eligible pts even prescribed this.
https://t.co/LoIdBvuIZj
Registration now open! Join us for a discussion of how the new #AFib guidelines pertain to #anticoagulation practitioners 💓
Wednesday, Feb. 21, 12pm ET
Moderators & panelists: @AAllenPharmD@AVB_AnticoagNP@AArmbruster09 ❤️🔥
Register today! https://t.co/blYyVd3kyZ
The 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis & Management of #AFib provides updated guidance for clinicians and emphasizes a rhythm control strategy & the need for lifestyle & risk factor modification in addition to medical treatment. Read the full guideline: https://t.co/YdOoI3s7QS
Now this is how to do an assessment of value for pharmacists' services! We need more formal CEAs like this based on patient outcomes (⬇︎BP ➡︎ ⬇︎ CVD events) & less cost-avoidance studies based on interventions made. Kudos @VCUDPOSChair & coauthors. https://t.co/lVIrlO8r0U
New academic year, new title! I was promoted to the academic rank of Professor and was honored to receive the Joe E. Haberle Outstanding Educator of the Year award. Lucky to work with great people, teach great students and residents, and have a rewarding clinical practice!
TUNA2 for antithrombotic stewardship. Does your hospital have a process for identifying which patients are at increased risk of bleeding and could benefit from ASA deprescribing or initiation of PPI. Thanks @jekurlander for this great graphic! #ACForum23@AnticoagForum
Pharmacists highlighted as a critical member of the heart team. Dr. Walsh also highlighted training and certifications clinical pharmacists complete. @MissouriACC@ACCinTouch#cvteam
Top3 heart failure trials in October 2022: #CardioTwitter
🥇Managing HF in patients on dialysis @JCardFail
🥈 Hydrochlorothiazide vs chlorthalidone, what is the difference? @CircAHA
🥉HF drug treatment ➡️Inertia, y itration, and discontinuation: EVOLUTION HF @JACCJournals
This is an excellent overview of treating patients with ASCVD and other comorbidities!
Will unapologetically highlight the role of an expert #Pharmacist Dr. Kim Birtcher on the writing committee 💪